Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies

Xiao-Ning Gao1 · Ji Lin2 · Shu-Hong Wang1 · Wen-Rong Huang1 · Fei Li1 · Hong-Hua Li1 · Jing Chen1 · Li-Jun Wang1 · Chun-Ji Gao1 · Li Yu1 · Dai-Hong Liu1

Received: 13 June 2018 / Accepted: 17 August 2018 / Published online: 24 August 2018
© The Author(s) 2018

Abstract
Unmanipulated haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma. Relapse is the main cause of treatment failure for patients with relapsed/refractory disease or with very high-risk gene mutations such as TP53, TET2, and DNMT3a. In this study, we aimed to establish the tolerance and efficacy of prophylactic donor lymphocyte infusion (DLI) with G-CSF-primed peripheral blood progenitors for prevention of relapse in these very high-risk patients after haplo-PBSCT. The prophylactic DLI was given at a median of 77 days after transplantation in 31 of 45 consecutive patients with very high-risk leukemia/lymphoma. The median dose of CD3+ cells for infusion was 1.8 × 10^7/kg. The 100-day incidences of acute graft-versus-host disease (GVHD) grades 2–4 and 3–4 after DLI were 55.3% and 10.2%. The 2-year incidences of chronic GVHD and severe chronic GVHD were 52.0% and 18.2%. The 2-year incidences of non-relapse mortality and relapse were 33.1% and 32.5%. The 2-year probabilities of overall survival and relapse-free survival were 40.1% and 31.9%. Poor-risk gene mutations (p = 0.029), disease in non-remission status prior to transplantation (p = 0.005), and donors older than 40 years of age (p = 0.043) were associated with relapse after DLI. In multivariate analysis, disease in non-remission status prior to transplantation was an independent risk factor of relapse (hazard ratio = 4.079; p = 0.035). These data showed the feasibility of the prophylactic DLI in the haplo-PBSCT setting and the anti-leukemic efficacy in very high-risk leukemia/lymphoma.

Keywords Donor lymphocyte infusion · Stem cell transplantation · Peripheral blood · Graft-versus-host disease · Relapse

Introduction

The prognosis of acute leukemia or high-grade lymphoma in relapsed/refractory status is dismal [1, 2]. More recently, gene mutations, such as TP53, DNA-methyltransferase-3a (DNMT3a) or ten-eleven translocation-2 (TET2) mutation, have been identified by the next-generation sequencing technique as very high-risk molecular markers for acute leukemia with low rate of remission and short survival [3–5]. Though the targeted therapy developed in recent years have resulted in an increased rate of remission and improved survival in a small subset of these very high-risk patients, allogeneic hematopoietic stem cell transplantation (allo-HCT) is still the most effective way for cures. However, the recurrence of the underlying disease after transplantation remains the leading cause of treatment failure. The rate of relapse of the leukemia/lymphoma that was in refractory/relapsed status prior to transplantation and those with very high-risk gene mutations ranged from 50 to 60% and the long-term relapse-free survival (RFS) was less than 30% after allo-HCT [6, 7].

A reasonable approach to improve the survival of the very high-risk leukemia/lymphoma is to explore prophylactic strategies after transplantation to reduce the relapse rate. Donor
lymphocyte infusion (DLI) has been proved to be effective to stimulate graft-versus-leukemia (GVL) reaction in patients with minimal residual disease (MRD) or hematologic relapse after transplantation [8, 9]. However, the utility of DLI is limited by the toxicity of fatal GVHD or pancytopenia and subsequent infections resulting in an increase in non-relapse mortality (NRM). We have shown that using granulocyte colony-stimulating factor (G-CSF)-primed peripheral blood cells (G-PB) for DLI with substitution of the steady-state lymphocytes could reduce the DLI-associated fatal GVHD without counteracting its GVL effect [10]. Reduced GVHD with improved RFS has been established in the unmanipulated haploidentical-HCT with bone marrow and peripheral blood (BM + PB) as grafts. The safety and efficacy of prophylactic G-PB DLI in the setting of unmanipulated haploidentical PBSCT (haplo-PBSCT) have not been determined. In this study, we used prophylactic G-PB DLI for the very high-risk leukemia/lymphoma patients after haplo-PBSCT with modifications intending to alleviate DLI-associated GVHD. The modifications included that the dose of infused CD3+ cells was reduced to less than 2 $\times$ 10^7/kg (BM + PB setting, 4 $\times$ 10^7/kg), and the time interval between haplo-PBSCT and DLI was postponed to 60–90 days (BM + PB setting, 45–60 days). The data of tolerance and efficacy of prophylactic G-PB DLI in 31 patients with very high-risk features was presented.

Methods

Study design

We did a retrospective, observational cohort study of a total of 45 consecutive patients with very high-risk leukemia/lymphoma who underwent haplo-PBSCT in our center between March 1, 2014 and January 31, 2018 (Supplementary Table 1). All of the patients enrolled in this study have not been reported in previous study. They were given a haplo-PBSCT because of lacking matched sibling or unrelated donor. The very high-risk features were defined by the following criteria: (i) disease in non-remission (NR) status including primary induction failure or relapsed, (ii) acute leukemia achieving first complete remission (CR) with $>$ 2 cycles of induction of chemotherapy, (iii) leukemia with TET2, DNMT3a, or TP53 mutation, and (iv) leukemia with normal cytogenetics and FLT3-ITD or chronic myelogenous leukemia (CML) with BCR-ABL T315I mutation (due to unavailability of targeted therapy). The study was approved by the Ethics Committee of Chinese PLA General Hospital, and signed informed consents were obtained from all patients prior to transplantation in accordance with principles of Declaration of Helsinki.

The patients with very high-risk features with full donor chimerism and negative MRD would receive prophylactic DLI at days 60 to 90 after haplo-PBSCT if no GVHD developed. If GVHD occurred before day + 60, DLI was delayed to 8 weeks after disappearance of symptoms and signs of GVHD. The patients with infection before day + 60 would receive prophylactic DLI after 4 weeks of disappearance of symptoms and stable improvement of the signs of infection. The G-PB cells infused were thawed from the cryopreserved product at the time of graft collection. The number of CD3+ cells scheduled for infusion was 2 $\times$ 10^7/kg at a single dose. Cyclosporine A (CsA) started after transplant was not mandatory to stop prior to DLI. CsA was given at 2 mg/kg b.i.d from days $-$ 3 to + 90, then be tapered at 33% per month to be discontinued on days + 150 to + 180 unless GVHD developed. If the patients received prophylactic DLI before day + 90, CsA was used 6 weeks (though concentration 150–250 ng/ml) after DLI for prophylaxis of DLI-associated GVHD, and then tapered and discontinued within 2 weeks except GVHD was present. If GVHD occurred before day + 90, DLI would be delayed to 8 weeks after GVHD was well controlled and CsA would be continued until 6 weeks after DLI, and then tapered over 2 weeks except GVHD occurred. Patients with positive MRD or hematologic relapse before day + 60 received chemotherapy followed by preemptive or therapeutic DLI and were not evaluated in this study.

Transplantation procedure

For patients without organ dysfunction, the busulfan (Bu)-based myeloablative conditioning regimen was used, which consists of Bu (3.2 mg/kg, days $-$ 10 to $-$ 8), carmustine (250 mg/m^2, day $-$ 7), cytarabine (4 g/m^2, days $-$ 6 to $-$ 5), and cyclophosphamide (Cy; 50 mg/kg, days $-$ 4 to $-$ 3). For patients with organ dysfunction during chemotherapy, Cy was substituted with fludarabine (30 mg/m^2, days $-$ 7 to $-$ 3) due to organ dysfunction during chemotherapy. For patients with refractory B cell acute lymphoblastic leukemia, TBI-Cy regimen was used, which was consists of total body irradiation (8 Gy, day $-$ 7), cytarabine (4 g/m^2, days $-$ 6 to $-$ 5), and Cy (60 mg/kg, days $-$ 4 to $-$ 3). Anti-thymoglobuline (rabbit; Genzyme Europe BV; 2.5 mg/kg/d, days $-$ 5 to $-$ 2) was given to all recipients for prophylaxis of GVHD in addition to the routine regimen (CsA, mycophenolate mofetil, and short-term MTX). All recipients received G-PB as a source of graft. The supportive therapy was done as previously described [14].
Definitions and statistical analyses

All patients alive were followed-up from the date of graft infusion to March 31, 2018. Days prior to graft infusion was documented with “−” and those after graft infusion with “+.” Relapse was defined as hematologic recurrence of malignancies after HCT. GVHD and post-DLI GVHD were assessed as previously defined [15, 16]. NRM was defined as death from any cause without relapse. Cumulative incidences (CIs) of GVHD, viral reactivations, relapse, and NRM were analyzed in a competing risk framework using Gray’s method [17, 18]. Probabilities of RFS and OS were calculated with 95% confidence intervals using Kaplan-Meier estimates. Factors for univariate analysis of risk for GVHD, relapse, NRM, OS, or RFS were patient’s age (< 40 years vs. ≥ 40 years), donor’s age (< 40 years vs. ≥ 40 years), poor-risk gene mutations (no vs. yes), disease status at HCT (CR vs. NR), and the interval from diagnosis to transplant (< 6 months vs. ≥ 6 months). All variables associated with a p < 0.15 by univariate analyses were included into the multivariate analysis. Statistical analyses were performed using R statistical software with cmprsk package of (www.r-project.org), Stata 14.0 software, and SPSS 20.0 software.

Results

Implementation of the prophylactic DLI

Of the 45 patients with very high-risk features, 31 received the prophylactic DLI (Table 1 and supplementary Table 2). The median time of DLI was 77 (45–240) days after transplanation. The reasons for delay of DLI were GVHD (n = 12), pancytopenia (n = 3), and renal dysfunction due to hemorrhagic cystitis (n = 1). Patient 23 received prophylactic DLI on day +240 after HCT because of GVHD and cytomegalovirus-associated pancytopenia. The median doses of mononuclear cells and CD3+ cells for infusion were 0.6 (0.2–1.3) × 10^9/kg and 1.8 (0.4–6.9) × 10^7/kg, respectively. No onset of DLI-associated pancytopenia was documented in these patients.

A total of 14 patients with very high-risk features did not receive prophylactic DLI due to early relapse (n = 8), intermittent GVHD or infection and subsequent pancytopenia, and poor general condition (n = 6). Of the eight patients with early relapse, five had disease recurrence before day +60, and three developed GVHD and relapsed during the treatment of GVHD. The median time of relapse for these patients was 84.5 (36–168) days after haplo-PBSCT. Of the 14 patients without receiving scheduled prophylactic DLI treatment, eight died of relapse, two died of GVHD and four were still alive at the time of analysis. These four living patients recovered from GVHD and infections at 6 months post-transplantation with negative MRD, and they did not receive prophylactic DLI for tardy recovery from pancytopenia or poor general condition.

GVHD after the prophylactic DLI

Eighteen (58.1%) of the 31 patients who received prophylactic DLI developed acute GVHD grades 1–4 at a median of 64 (11–165) days after prophylactic DLI (grade 1 in 3 cases, grade 2 in 13 cases, grade 4 in 2 cases). Seven of the 13 patients with acute GVHD grade 2 died. Of these seven patients, one died of interstitial pneumonia, one died of intracranial hemorrhage, one died of disease relapse and three died of GVHD. Of the two patients with acute GVHD grade 4, one was cured and survived free of relapse and another one died of disease relapse. The CIs of acute GVHD grades 2–4 and 3–4 were 55.3% (95% CI 33.7–72.4%) and 10.2% (95% CI 1.6–28.6%) at 100 days after DLI, respectively (Fig. 1a). No factors tested significantly correlated with the risk of occurrence of acute GVHD in univariate analysis (Table 2).

Chronic GVHD occurred in 12 (38.7%; mild in 5 cases, moderate in 5 cases, severe in 4 cases) patients. The median time of the onset of chronic GVHD was 205 (60–582) days after DLI. Nine patients with chronic GVHD had previous acute GVHD after DLI. The 6-month, 1-year, and 2-year CIs of chronic GVHD were 20.6% (95% CI 8.1–37.0%), 42.1% (95% CI 21.9–61.2%), and 52.0% (95% CI 24.6–73.7%), respectively (Fig. 1c). The 6-month, 1-year, and 2-year CIs of severe chronic GVHD were 6.7% (95% CI 1.1–19.5%), 18.2% (95% CI 4.7–38.6%), and 18.2% (95% CI 4.7–38.6%), respectively (Fig. 1b). No factors tested significantly correlated with the risk of occurrence of chronic GVHD in univariate analysis (Table 2).

NRM and relapse of the prophylactic DLI recipients

A total of eight patients (25.8%) died of non-relapse complications. Of these eight patients, five died of GVHD, two died of pneumonia and respiratory failure, and one with poor engraftment died of intracranial hemorrhage. No pathogens were recorded for the two patients died of pneumonia. The 6-month, 1-year, and 2-year CIs of NRM were 6.7% (95% CI 1.1–19.5%), 24.7% (95% CI 10.5–42.0%), and 33.1% (95% CI 13.1–54.9%), respectively (Fig. 1c). The cumulative risk of NRM after prophylactic DLI was higher in the patients older than 40 years of age as compared with those younger than 40 years of age (p = 0.015; Table 2). A total of 6/12 patients older than 40 years of age died of non-relapse complications. Of the six patients, four died of GVHD and two died of pneumonia.

Nine patients (29.0%) relapsed at a median of 87 (11–332) days after prophylactic DLI and 209 (87–656) days after HCT. The 6-month, 1-year, and 2-year CIs of relapse after HCT were 19.9% (95% CI 7.9–35.8%), 32.5% (95% CI
15.5–50.7%), and 32.5% (95% CI 15.5–50.7%), respectively (Fig. 1d). Poor-risk gene mutations \((p = 0.029)\), NR status prior to HCT \((p = 0.005)\), and donors older than 40 years of age \((p = 0.043)\) correlated with a higher risk of relapse in univariate analyses (Table 2). In multivariate analysis, disease in NR status prior to HCT had the highest significant impact on relapse (hazard ratio = 4.079; \(p = 0.035\); Table 3). Of the nine patients with relapse after prophylactic DLI, six were in
NR status before transplantation. The median time of relapse for the six patients with pre-HCT NR disease was 114 (11–332) days after prophylactic DLI and 208 (87–379) days after transplantation.

Survival and the quality of life of the prophylactic DLI recipients

Median follow-up after haplo-PBSCT among surviving prophylactic DLI recipients was 383 (111–1174) days. At the time of analysis, 14/31 (45.2%) prophylactic DLI recipients were still alive in CR at a median of 274 (41–1129) days post-DLI. The Kaplan–Meier estimates for OS from transplantation at 1 and 2 years were 58.5% (95% CI 37.2–74.8%) and 40.1% (95% CI 16.3–63.1%; Fig. 1e). Estimated RFS from transplantation at 1 and 2 years was 47.3% (95% CI 28.0–64.4%) and 31.9% (95% CI 11.7–54.5%; Fig. 1f). The quality of life in prophylactic DLI recipients who survived without relapse was measured with Karnofsky performance scores. Twelve patients were 90–100, one was 80 and one was 50 due to chronic GVHD. No factors tested significantly correlated with OS or RFS in univariate analysis (Table 2).

Discussion

The recurrence of disease is the primary cause of treatment failure and mortality after allo-HCT for patients with very high-risk hematologic malignancies. Prophylactic DLI has been proved effective for treatment, intervention, or prophylaxis of relapse when targeted therapy is lacking post-transplantation. Here, we showed the feasibility of G-PB DLI in the unmanipulated haplo-PBSCT setting with G-CSF primed PB as the graft source for prophylaxis of relapse in the very high-risk patients.

In previous study of transplantation with BM or with BM combined with PBSC as graft, we have shown that the incidence of severe GVHD after G-PB DLI was less compared with that after traditional DLI with steady-state lymphocytes [19]. In subsequent series of studies, the safety and efficacy of G-PB DLI were demonstrated in the treatment of relapse, preemptive therapy for MRD-positive patients or prophylaxis before relapse occurs after unmanipulated haploidentical HCT with PB + BM as grafts. It was reported that in 56 patients (29 after haplo-HCT) who were MRD-positive and received G-PB DLI, the incidence of acute GVHD grades 2–4 was 27.9% and that of chronic GVHD was 42.9% which were similar to those in the MRD negative patients (30.2 and 38.8%) who did not receive the intervention [20]. The use of G-PB DLI was based on the laboratory findings that G-CSF-priming could induce hypo-responsiveness of T cells for polarization from Th1 to Th2 and downregulation of the CD28/B7 pathway [10, 21] and augment NK-T cell dependent CD8⁺ cytotoxicity which might enhance GVL without GVHD [22]. Further, there was no less activity with G-CSF-primed as compared to untreated T cells [23]. Nevertheless, the evidence for G-CSF-priming retaining GVL activity is sparse. In the current transplantation setting without in vitro T cell depletion, there is little evidence that NK cells could replace the hindered T cells. Therefore, the delay of DLI for 60 days might be the most important reason for its tolerance, as the cytokine storm caused by myeloablative conditioning was over.

It has been shown that G-PB DLI with immunosuppressants prophylaxis more than 6 weeks were associated with a lower incidence of acute GVHD grades 3–4. Further, DLI-associated acute GVHD grades 3–4 was the only risk factor for OS and NRM but not for relapse after DLI [11]. Therefore, in the current study, CsA was reduced and discontinued after the 6-week prophylaxis if no GVHD occurred. PBSCT with HLA-identical sibling donors was considered to be associated with an increased incidence of chronic GVHD compared with allo-HCT with BM [24]. Therefore, we postponed the timing for DLI and reduced the dose of infused CD3⁺ cells concerning the potential higher incidence of GVHD in the haplo-PBSCT setting. The incidences of DLI-associated acute GVHD grades 2–4, 3–4, chronic GVHD, and NRM in our study were 55.3%, 10.2%, 52.0%, and 33.1%, respectively.
Table 2  Univariate analysis for the risk factors of transplant outcomes in prophylactic DLI recipients

| Variable                        | Grades II–IV acute GVHD | Grades III–IV acute GVHD | Chronic GVHD | NRM     | Relapse | RFS     | OS      |
|---------------------------------|--------------------------|---------------------------|--------------|---------|---------|---------|---------|
|                                 | % (95% CI) p value       | % (95% CI) p value        | % (95% CI) p value | % (95% CI) p value | % (95% CI) p value | % (95% CI) p value | % (95% CI) p value |
| Age                             |                          |                           |              |         |         |         |         |
| < 40 years old                  | 53.6 (26.2–74.8) 0.505  | 15.3 (2.1–40.1) 0.312    | 55.2 (16.4–82.2) 0.942 | 5.6 (0.3–23.3) 0.018 | 40.6 (17.2–63.0) 0.214 | 35.9 (8.2–65.7) 0.409 | 44.3 (12.1–73.1) 0.213 |
| ≥ 40 years old                  | 56.8 (19.9–82.1)         | 0                         | 41.7 (13.5–68.2) | 55.2 (18.6–81.1) | 20.5 (1.9–53.1) | 24.3 (4.1–53.4) | 36.5 (10.2–64.0) |
| Poor-risk gene mutations        |                          |                           |              |         |         |         |         |
| No                              | 50.0 (15.7–77.2) 0.635  | 13.0 (0.4–46.3) 0.838    | 54.6 (18.2–80.6) 0.391 | 18.2 (2.3–46.2) 0.345 | 54.6 (19.9–79.6) 0.029 | 27.3 (6.5–53.9) 0.131 | 30.9 (10.6–67.3) 0.600 |
| Yes                             | 58.6 (28.7–79.6)         | 8.6 (0.4–33.7)           | 43.1 (14.0–69.8) | 29.9 (9.9–53.4) | 18.0 (3.9–40.5) | 26.1 (1.8–63.6) | 31.5 (1.8–71.7) |
| Disease status at transplantation |                          |                           |              |         |         |         |         |
| CR                              | 55.9 (30.1–75.5) 0.889  | 6.8 (0.4–27.5) 0.526     | 40.8 (16.2–64.4) 0.346 | 49.1 (11.0–79.5) 0.194 | 14.3 (3.4–32.6) 0.005 | 36.7 (8.6–66.3) 0.130 | 47.5 (16.2–73.7) 0.371 |
| NR                              | 54.2 (10.6–84.6)         | 17.9 (0.3–60.6)          | 48.2 (10.2–79.1) | 11.0 (0.4–41.7) | 74.1 (17.6–95.0) | 14.8 (0.8–46.8) | 23.3 (1.3–61.6) |
| Donor’s age                     |                          |                           |              |         |         |         |         |
| < 40 years old                  | 60.2 (33.3–79.1) 0.362  | 6.9 (0.4–28.0) 0.397     | 52.9 (20.1–77.7) 0.577 | 43.2 (16.4–67.7) 0.131 | 24.0 (8.1–44.4) 0.043 | 32.8 (11.2–56.7) 0.493 | 35.6 (11.3–61.2) 0.778 |
| ≥ 40 years old                  | 43.8 (7.7–76.6)          | 17.5 (0.4–57.1)          | 14.6 (0.4–50.9) | 0       | 41.7 (7.2–74.7) | 43.8 (10.1–74.2) | 65.6 (15.7–90.9) |
| Time from diagnosis to transplantation |                      |                           |              |         |         |         |         |
| < 6 months                      | 63.3 (29.0–84.5) 0.352  | 10.7 (0.4–40.0) 0.922    | 53.8 (11.2–83.9) 0.827 | 34.2 (11.2–59.1) 0.531 | 19.4 (4.3–42.4) 0.145 | 46.4 (20.4–69.0) 0.415 | 45.0 (19.2–68.0) 0.492 |
| ≥ 6 months                      | 49.0 (18.1–74.3)         | 10.6 (0.4–39.6)          | 48.8 (16.2–75.4) | 32.3 (3.0–69.4) | 49.7 (16.5–76.3) | 18.0 (1.3–50.9) | 20.9 (1.0–58.6) |

CR, complete remission; NR, non-remission; GVHD, graft-versus-host disease; NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival; CI, confidence interval
Table 3  Multivariate analysis for the risk factors of relapse in prophylactic DLI recipients

| Variable                        | HR   | 95% CI     | p value |
|---------------------------------|------|------------|---------|
| High-risk gene mutations        |      |            |         |
| No                              | 1    |            |         |
| Yes                             | 0.499| 0.136–1.830| 0.300   |
| Disease status at transplantation|      |            |         |
| CR                              | 1    |            |         |
| NR                              | 4.079| 1.105–15.060| 0.035  |
| Donor’s age                     |      |            |         |
| < 40 years old                  | 1    |            |         |
| ≥ 40 years old                  | 3.102| 0.884–10.890| 0.077  |
| Time from diagnosis to transplantation |    |            |         |
| < 6 months                      | 1    |            |         |
| ≥ 6 months                      | 1.800| 0.545–5.940| 0.330  |

Cl, confidence interval; CR, complete remission; HR, hazard ratio; NR, non-remission

In the patients who received haplo-PBSCT in our unit before January of 2015 [14], the incidences of acute GVHD grades 2–4, 3–4, chronic GVHD, and NRM were 36.1%, 14.5%, 38.4%, and 24.0%, respectively. Though the incidences of GVHD between these two cohort studies should not be compared directly, it seemed that G-PB DLI did not result in an intolerable toxicity in terms of GVHD and NRM. In addition, the tolerance of this procedure might be related to the following mastery of contraindications for prophylactic DLI: (1) the elimination of the patients with intermittent GVHD and (2) all prophylactic DLI was given after stable response of treatment of the previous GVHD.

An optimal timing of prophylactic DLI should be in a balance between GVL and GVHD because increasing the time interval between transplantation and DLI will lead to a decrease in the risk of DLI-associated toxicity but an increase in the likelihood of relapse. Because the median time to post-allo-HCT relapse or progression was 2 to 3 months for adult patients with high-risk acute myeloid leukemia and T cell leukemia/lymphoma [25, 26], it is reasonable to administrate the prophylactic strategy before day + 90 after HCT. The median time of the occurrence of acute GVHD in the unmanipulated haplo-PBSCT was +30~+60 days after graft infusion. That means the prophylactic DLI candidates would face superimposed risk of GVHD if the time of DLI is before day +60. Even though several patients, at the beginning stage of the current study, had received DLI before day +60, it is reasonable and feasible to give the prophylactic DLI after day +60 if no intermittent GVHD occurred or GVHD was stably controlled.

Considering the different kinetics and sensitivity of GVL response in hematologic malignancies enrolled in this study, the relapse and survival could not have been compared with other reports. In the current study, a total of six patients with a disease in NR status prior to transplantation relapsed at a median of 114 days after DLI, and the statistical analysis revealed that disease in NR status prior to transplantation was an independent risk factor for relapse after DLI. Reasons for the treatment failure might be associated with the poor GVL effect of DLI. The high proliferative kinetics of leukemia cells is one cause for poor GV effect of DLI. Nevertheless, the immune evasion of leukemia cells by mechanisms such as loss of the patient-specific HLA haplotype represents another cause for poor GV effect of DLI [27]. Therefore, it is likely the future of DLI should involve more strategies to enhance the GVL effect of the infused donor cells via using cytokines like interferon [28], selection or depletion of specific donor lymphocytes subsets [29, 30], genetically modified donor lymphocytes targeting of tumor-specific antigens, second prophylactic DLI in case of no GVHD occurrence, or combination with target therapy.

In summary, the data from this study suggested the tolerance and efficacy of prophylactic DLI in patients with very high-risk leukemia/lymphoma in the unmanipulated haplo-PBSCT setting with PB as grafts. Further study is required to determine kinetics of relapse in each subtype of high-risk malignancies and the optimal long-term prophylactic strategy.

Funding  This work was partially supported by grants from the National Natural Science Foundation of China (81770203 to D-H L, 81670135 and 81870109 to X-N G), Beijing Natural Science Foundation (7162174 to J L) and National Clinical Specialist Focus on Military Construction Projects.

Compliance with ethical standards

Conflict of interest statement  The authors declare that they have no conflict of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götz K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glastmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorf A, Benner A, Döhner H (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28(30):4642–4648
2. Schmid C, Schleuning M, Ledderose G, Fischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and
prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675–5687

3. Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rössler W, Serve H, Hänel M, Sohlbach K, Klessie C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J. Study Alliance Leukaemia (SAL) (2016) TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol 172(6):914–922

4. Hemmati PG, Vuong LG, Terwey TH, Jehn CF, le Coutre P, Penack O, Na IK, Dörken B, Arnold R (2017) Predictive significance of the European LeukaemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation. Eur J Haematol 98(2):160–168

5. AHN JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Lee IK, Kim NY, Minden MD, Jung CW, Jang HJ, Kim HJ, Moon JH, Sohn SK, Won HJ, Kim SH, Kim N, Yoshida K, Ogawa S, Kim DD (2017) Adverse prognostic effect of homoygous TET2 mutation on the relapse risk of acute myeloid leukaemia in patients of normal karyotype. Haematologica 100(9):e351–e353

6. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kambale R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DJ, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730–3738

7. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Arzt A, Stock W (2013) A novel clonofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant 48(11):1437–1443

8. Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC, Spyridonidis A (2013) High alloreactivity of Tcells after in vitro mixture of CDs56high NKT cells and donor lymphocytes after allogeneic bone marrow transplantation. J Peking Unib Health Sci 35:103–107

9. Scrucca L, Santucci A, Aversa F (2007) Regression modeling of GVL effectiveness and polarization potential of T cells in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 17(3):193–197

10. Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, Bofinger HM, Burman AC, Oliver JD, Kienszle N, Porcelli SA, Pellieci DG, Godfrey DI, Smyth MJ, Hill GR (2005) NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 115(11):3093–3103

11. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Bekscak M, Hasenclever D, Socci G, Schmitz N (2010) Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial. Lancet Oncol 11(4):331–338

12. Hasskarl J, Zerweck A, Ihorst G, Bertz H, Finke J (2012) clofarabine bridge strategy facilitates allogeneic transplantation in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 47(2):277–282

13. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, Han W, Wang LL, Wang L, Li WJ, Yu L, Liu DH (2017) Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies. Br J Haematol 176(1):92–100

14. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):81–387

15. Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388–1395

16. Huang XJ, Guo NL, Ren HY (2003) The comparison of GVL effects between the patients receiving donor peripheral blood stem cells and donor lymphocytes after allogeneic bone marrow transplantation. J Peking Unib Health Sci 35:103–107

17. Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388–1395

18. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):81–387

19. Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388–1395

20. Huang XJ, Guo NL, Ren HY (2003) The comparison of GVL effects between the patients receiving donor peripheral blood stem cells and donor lymphocytes after allogeneic bone marrow transplantation. J Peking Unib Health Sci 35:103–107

21. YAN CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119(4):3256–3262

22. Huang XJ, Chang YJ, Zhao XY (2007) Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 17(3):193–197

23. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Bekscak M, Hasenclever D, Socci G, Schmitz N (2010) Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial. Lancet Oncol 11(4):331–338

24. Hasskarl J, Zerweck A, Ihorst G, Bertz H, Finke J (2012) clofarabine bridge strategy facilitates allogeneic transplantation in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 47(2):277–282

25. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, Chen YH, Han W, Wang FR, Wang JZ, Yan CH, Huang XJ (2012) Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 47(8):1099–1104

26. Inoue Y, Fuji T, Tonomaski Y, Tanaka T, Ito A, Okinaka K, Kurosawa S, Kim SW, Nakagama H, Fukuda T (2018)
Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant. https://doi.org/10.1038/s41409-018-0139-z

27. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361(5):478–488

28. Gesundheit B, Shapira MY, Resnick IB, Amar A, Kristt D, Dray L, Budowski E, Or R (2009) Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation. Am J Hematol 84(3): 188–190

29. Meyer RG, Britten CM, Wehler D, Bender K, Hess G, Konur A, Hartwig UF, Wehler TC, Ullmann AJ, Gentilini C, Uharek L, Huber C, Kolbe K, Herr W (2007) Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 109(1):374–382

30. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanesi M, Longoni P, Gandola L, Lombardo C, Corradini P (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 113(19):4771–4779